Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux SC versus continuous IV infusion in ICU patients
2007-004911-79Phase 4Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Oct 2007
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Anti-factor Xa activity over 24 hours. Started Oct 2007; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2007-004911-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004911-79.